Screening for Treatment-Related Sarcopenia in Cancer Care

Abstract

Treatment-related sarcopenia is an increasingly recognized complication in oncology, characterized by progressive muscle loss and impaired function in patients undergoing cancer therapies. Early identification through effective screening is pivotal for optimizing outcomes, as sarcopenia is associated with heightened morbidity, reduced physical performance, and diminished survival. This review synthesizes current clinical evidence, discusses underlying mechanisms, and evaluates practical screening approaches for treatment-induced sarcopenia in cancer care, emphasizing the necessity for guideline-based interventions to mitigate risks and improve patient quality of life.

Introduction

Cancer therapies, while essential for disease control, frequently contribute to adverse musculoskeletal outcomes, notably sarcopenia. Defined by decreased skeletal muscle mass and function, sarcopenia in cancer patients is multifactorial, often arising from the direct effects of cytotoxic agents, nutritional deficits, systemic inflammation, and reduced physical activity. The clinical significance of treatment-related sarcopenia extends beyond functional impairment, influencing response to therapy, recovery trajectories, and overall survival. Consequently, systematic screening for sarcopenia has emerged as an integral component of comprehensive oncologic care, underscoring the need for evidence-based protocols, timely diagnosis, and multidisciplinary management strategies.

Epidemiology / Disease Burden

The prevalence of sarcopenia among cancer patients varies widely, influenced by cancer type, stage, treatment modality, and patient demographics. Meta-analyses report rates ranging from 15% to over 50% in various malignancies, with higher incidence observed in gastrointestinal, lung, and head and neck cancers. Treatment-related sarcopenia is particularly prominent in patients receiving chemotherapy, radiotherapy, or targeted therapies, and is often underdiagnosed due to lack of routine assessment. The burden is substantial: sarcopenic patients exhibit increased rates of chemotherapy toxicity, unplanned hospitalizations, postoperative complications, and mortality, highlighting the imperative for standardized screening protocols in oncology practice.

Pathophysiology

The mechanisms underlying treatment-induced sarcopenia are complex and multifactorial. Chemotherapeutic agents can induce mitochondrial dysfunction, oxidative stress, and direct myotoxicity, resulting in muscle protein breakdown. In addition, systemic inflammation, characterized by elevated cytokines such as IL-6 and TNF-α, promotes catabolic pathways and suppresses muscle protein synthesis. Anorexia, malnutrition, and gastrointestinal toxicity further exacerbate negative energy balance, while prolonged bed rest and physical inactivity contribute to muscle atrophy. Hormonal dysregulation, including alterations in testosterone, insulin-like growth factor-1, and glucocorticoids, also play contributory roles. These factors collectively create a milieu conducive to accelerated muscle loss in cancer patients undergoing active therapy.

Risk Factors

Several risk factors predispose cancer patients to developing treatment-related sarcopenia. Advanced age, low baseline muscle mass, poor nutritional status, and pre-existing comorbidities such as diabetes or chronic kidney disease increase vulnerability. Certain tumor types and locations (e.g., gastrointestinal, pancreatic, head and neck) inherently carry higher risk due to tumor-induced cachexia and malabsorption. The intensity and duration of cancer therapy, particularly with platinum-based chemotherapeutics, corticosteroids, or radiation involving large fields, also elevate risk. Additional contributors include inadequate physical activity, depression, and social factors that limit access to supportive care resources. Identification of high-risk patients through comprehensive assessment is critical for targeted intervention.

Clinical Features

Treatment-related sarcopenia may initially present subclinically, with overt features developing as muscle loss progresses. Patients commonly report generalized fatigue, weakness, and reduced exercise tolerance. Objective findings include decreased grip strength, impaired gait speed, and difficulties with activities of daily living. In advanced cases, muscle wasting becomes visually evident, and patients may experience increased risk of falls, fractures, and impaired wound healing. Sarcopenia also negatively impacts functional independence and correlates with diminished chemotherapy tolerance, higher rates of dose reductions, and interruptions in treatment schedules, thereby influencing disease outcomes.

Diagnosis

Timely and accurate diagnosis of treatment-related sarcopenia is essential for effective management. The gold standard involves a combination of muscle mass assessment (usually via CT or MRI imaging at the L3 vertebral level), muscle strength testing (grip dynamometry), and functional performance measures (gait speed, chair stand test). The European Working Group on Sarcopenia in Older People (EWGSOP2) criteria and the Asian Working Group for Sarcopenia (AWGS) guidelines provide standardized diagnostic algorithms, integrating both quantitative and functional parameters. In oncology, opportunistic use of routine cross-sectional imaging offers a practical approach for muscle mass evaluation. Screening tools such as the SARC-F questionnaire and physical performance batteries (e.g., Short Physical Performance Battery) can aid in risk stratification, though their sensitivity in cancer populations requires further validation.

Treatment & Management

Management of treatment-related sarcopenia necessitates a multidisciplinary approach encompassing nutritional, pharmacologic, and exercise-based interventions. Nutritional support, with an emphasis on adequate protein and caloric intake, is foundational, often requiring input from dietitians specialized in oncology. Resistance and aerobic exercise regimens have demonstrated efficacy in improving muscle mass and function, even during active cancer treatment. Pharmacological options—such as anabolic agents, selective androgen receptor modulators, and anti-inflammatory medications—are under investigation, though robust evidence for routine use remains limited. Early intervention, individualized care plans, and consistent follow-up are crucial for optimizing patient outcomes and minimizing functional decline.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the understanding and management of treatment-related sarcopenia. Novel biomarkers, including myostatin, activin A, and circulating microRNAs, are being explored for early detection and risk stratification. Digital health technologies, such as wearable devices and tele-rehabilitation platforms, enable remote monitoring of physical performance and facilitate personalized exercise interventions. Emerging pharmacotherapies targeting muscle anabolism and anti-inflammatory pathways are under clinical investigation, with agents like bimagrumab and ghrelin mimetics showing promise in early-phase trials. Integration of artificial intelligence for automated muscle mass quantification from routine imaging holds potential for widespread screening in oncology settings.

Guideline Recommendations

International guidelines increasingly recognize the importance of screening and managing sarcopenia in cancer care. The European Society for Clinical Nutrition and Metabolism (ESPEN) and the American Society of Clinical Oncology (ASCO) advocate for routine nutritional and functional assessment at key treatment milestones. Screening for sarcopenia should be incorporated into standard oncologic care, particularly for high-risk populations. Multidisciplinary collaboration, including oncologists, dietitians, physiotherapists, and geriatricians, is emphasized for comprehensive management. Ongoing education and training in sarcopenia assessment and intervention are recommended to improve clinician awareness and patient outcomes.

Conclusion

Sarcopenia represents a prevalent and clinically significant complication in cancer care, particularly as a consequence of modern oncologic therapies. Routine screening, early diagnosis, and tailored interventions are essential for mitigating risks, preserving functional independence, and enhancing survival. Continued research into mechanistic pathways, novel biomarkers, and emerging therapies will refine strategies for prevention and management. Integrating guideline-based screening into standard cancer care pathways remains a critical step toward optimizing patient outcomes and quality of life in the era of personalized oncology.